Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Optimal drug delivery for intraperitoneal paclitaxel (PTX) in murine model.

Kitayama J, Ishigami H, Yamaguchi H, Yamada J, Soma D, Miyato H, Kamei T, Lefor AK, Sata N.

Pleura Peritoneum. 2017 Jun 1;2(2):95-102. doi: 10.1515/pp-2017-0002. Epub 2017 Mar 30.

2.

Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) for peritoneal dissemination of gastric cancer.

Soma D, Kitayama J, Konno T, Ishihara K, Yamada J, Kamei T, Ishigami H, Kaisaki S, Nagawa H.

Cancer Sci. 2009 Oct;100(10):1979-85. doi: 10.1111/j.1349-7006.2009.01265.x. Epub 2009 Jun 26.

3.

Antitumor effect and pharmacokinetics of intraperitoneal NK105, a nanomicellar paclitaxel formulation for peritoneal dissemination.

Emoto S, Yamaguchi H, Kishikawa J, Yamashita H, Ishigami H, Kitayama J.

Cancer Sci. 2012 Jul;103(7):1304-10. doi: 10.1111/j.1349-7006.2012.02274.x. Epub 2012 Apr 19.

4.

Spatial distribution of intraperitoneally administrated paclitaxel nanoparticles solubilized with poly (2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate) in peritoneal metastatic nodules.

Kamei T, Kitayama J, Yamaguchi H, Soma D, Emoto S, Konno T, Ishihara K, Ishigami H, Kaisaki S, Nagawa H.

Cancer Sci. 2011 Jan;102(1):200-5. doi: 10.1111/j.1349-7006.2010.01747.x. Epub 2010 Oct 13.

5.

Therapeutic effect of intravesical administration of paclitaxel solubilized with poly(2-methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate) in an orthotopic bladder cancer model.

Tamura K, Kikuchi E, Konno T, Ishihara K, Matsumoto K, Miyajima A, Oya M.

BMC Cancer. 2015 Apr 26;15:317. doi: 10.1186/s12885-015-1338-2.

7.

Intraperitoneal paclitaxel induces regression of peritoneal metastasis partly by destruction of peripheral microvessels.

Kitayama J, Emoto S, Yamaguchi H, Ishigami H, Watanabe T.

Cancer Chemother Pharmacol. 2014 Mar;73(3):605-12. doi: 10.1007/s00280-014-2393-0. Epub 2014 Jan 25.

PMID:
24464356
8.

Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxel.

Wada M, Jinno H, Ueda M, Ikeda T, Kitajima M, Konno T, Watanabe J, Ishihara K.

Anticancer Res. 2007 May-Jun;27(3B):1431-5.

9.

Thermosensitive hydrogel system assembled by PTX-loaded copolymer nanoparticles for sustained intraperitoneal chemotherapy of peritoneal carcinomatosis.

Xu S, Fan H, Yin L, Zhang J, Dong A, Deng L, Tang H.

Eur J Pharm Biopharm. 2016 Jul;104:251-9. doi: 10.1016/j.ejpb.2016.05.010. Epub 2016 May 14.

PMID:
27185379
10.

Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers.

Konno T, Watanabe J, Ishihara K.

J Biomed Mater Res A. 2003 May 1;65(2):209-14.

PMID:
12734814
11.

Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis.

Kobayashi D, Ishigami H, Kanda M, Tanaka C, Yamaguchi H, Kitayama J, Kodera Y.

Oncology. 2019 Sep 5:1-5. doi: 10.1159/000502484. [Epub ahead of print]

PMID:
31487733
12.

Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors.

Bajaj G, Kim MR, Mohammed SI, Yeo Y.

J Control Release. 2012 Mar 28;158(3):386-92. doi: 10.1016/j.jconrel.2011.12.001. Epub 2011 Dec 9. Erratum in: J Control Release. 2012 Aug 20;162(1):257.

13.

Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo.

Zhong Y, Goltsche K, Cheng L, Xie F, Meng F, Deng C, Zhong Z, Haag R.

Biomaterials. 2016 Apr;84:250-261. doi: 10.1016/j.biomaterials.2016.01.049. Epub 2016 Jan 23.

PMID:
26851390
14.

Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.

Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe T, Shoji M, Okamoto K, Nakanuma S, Sakai S, Makino I, Furukawa H, Hayashi H, Nakamura K, Inokuchi M, Nakagawara H, Miyashita T, Tajima H, Takamura H, Ninomiya I, Fujimura T, Masakazu Y, Hirakawa K, Ohta T.

Oncol Rep. 2014 Jul;32(1):89-96. doi: 10.3892/or.2014.3210. Epub 2014 May 23.

PMID:
24859429
15.

Breakthrough therapy for peritoneal carcinomatosis of gastric cancer: Intraperitoneal chemotherapy with taxanes.

Yamaguchi H, Kitayama J, Ishigami H, Kazama S, Nozawa H, Kawai K, Hata K, Kiyomatsu T, Tanaka T, Tanaka J, Nishikawa T, Otani K, Yasuda K, Ishihara S, Sunami E, Watanabe T.

World J Gastrointest Oncol. 2015 Nov 15;7(11):285-91. doi: 10.4251/wjgo.v7.i11.285. Review.

16.

An in vivo mechanism for the reduced peripheral neurotoxicity of NK105: a paclitaxel-incorporating polymeric micellar nanoparticle formulation.

Nakamura I, Ichimura E, Goda R, Hayashi H, Mashiba H, Nagai D, Yokoyama H, Onda T, Masuda A.

Int J Nanomedicine. 2017 Feb 15;12:1293-1304. doi: 10.2147/IJN.S114356. eCollection 2017.

17.

Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.

Vassileva V, Grant J, De Souza R, Allen C, Piquette-Miller M.

Cancer Chemother Pharmacol. 2007 Nov;60(6):907-14. Epub 2007 Mar 21.

PMID:
17375303
18.

Intraperitoneal delivery of paclitaxel by poly(ether-anhydride) microspheres effectively suppresses tumor growth in a murine metastatic ovarian cancer model.

Yang M, Yu T, Wood J, Wang YY, Tang BC, Zeng Q, Simons BW, Fu J, Chuang CM, Lai SK, Wu TC, Hung CF, Hanes J.

Drug Deliv Transl Res. 2014 Apr 1;4(2):203-9. doi: 10.1007/s13346-013-0190-7.

19.

Development of targeted therapy with paclitaxel incorporated into EGF-conjugated nanoparticles.

Shimada T, Ueda M, Jinno H, Chiba N, Wada M, Watanabe J, Ishihara K, Kitagawa Y.

Anticancer Res. 2009 Apr;29(4):1009-14.

20.

S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis.

Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S.

Gastrointest Cancer Res. 2012 May;5(3 Suppl 1):S10-3.

Supplemental Content

Support Center